



veeda clinical research®



# Unleashing the Power of India

India ■ England ■ Belgium ■ USA ■ Paris




# Indian Regulatory Affairs

Dr. Kiran Marthak

Director

Veeda Clinical Research



# Contents

- DCGI & responsibilities
- Schedule Y
- Requirements for Phase I clinical Trials/BA BE Studies , Phase II , Phase III, Adverse event reporting, Biotech products and Medical Devices
- Summary-Regulatory Approval process flowchart for India Phase I /BA-BE
- India versus the World--Clinical trial application Review Period
- DCGI approvals- Yearly Trends
- Q & A

# DCGI & responsibilities




Drug Controller General (I) is head of the Indian Drug Regulatory Authority, who ensure that all the medicinal products will be manufactured, distributed and marketed with good quality, safety and efficacy until they reach to the patients.

## **Responsibilities of DCGI**

- Approval/NOC for Clinical trials, Bioequivalence studies and Marketing permission in India
- Approval for Test License
- Testing of Drugs
- Registration for Import and Licensing
- Export NOCs-Biological samples, Drugs, etc.
- Licensing of Blood Banks, r-DNA products, Vaccines and Medical Device
- Amendment in Drugs And Cosmetics Acts and Rules from time to time

# Schedule Y



Schedule Y deals with regulations relating to clinical trial requirements for import, manufacture and obtaining marketing approval for a new drug in India.

Rule 122 A - Application for permission to import new drug.

Rule 122 B - Application for permission to manufacture new drug.

Rule 122 D - Application for permission to import /manufacture FDC

Rule 122 DA –Application for permission to conduct clinical trials

Rule 122 E – Definition of New Drugs\*

- \*New Substance having therapeutic indication

- \*Modified or new claims, indications, dosage, dosage form and new route of administration for already approved drug.


- \*Fixed Dose Combination, individually approved earlier now for modified claim

- \*Vaccines are new drugs unless otherwise certified

- \*Considered new drug for 4 years from date of first approval or inclusion in IP

# Requirements-Phase I CT Applications

molecules - discovered in India




## SECTION A

### 1) GENERAL INFORMATION INCLUDE

- Introduction about Company
- Administrative Headquarters
- Manufacturing Facilities
- Regulatory permissions/approvals
  - a) No objection certificate for Form-29 as issued by DCGI
  - b) Form 29 as issued by State Licensing Authority
- Regulatory and intellectual property status in other countries( if any)
  - Countries where the drug is marketed, approved as IND along with details i.e. Withdrawn, with reasons if any.
- Patent information status in India & other countries

# Requirements-Phase I CT Applications

molecules -discovered in India



## Section B

### 1. CHEMISTRY MANUFACTURING CONTROL which includes


- Product Description
- Name of the product
- Generic name / INN name
- Route of administration
- Dosage of strength
- Qualitative and Quantitative Composition
- Product Development

### 2. STRAIN DETAILS

- Name and source (if any)
- In case of products derived from r-DNA technology, the following details shall also be furnished
- Clone development (for recombinant products)
- Details on source Nucleic acid
- Vector(s)- *Details about vector, please enclose the map of the vector gene*
- Host(s) that carrying the vector(s)/ target gene(s) :
- Substrate details (For cell culture based products)--Details of name and source of substrate
- Master seed and Working seed details

# Requirements-Phase I CT Applications

molecules discovered in India



## Section B continued.....

### 3. Information on Drug Substance


- Production of Drug substance
- Characterization of Drug substance
- Control of Drug substance
- Reference standard materials
- Stability data

### 4. Information on Drug Product

- Description & composition
- Components of Drug product
- Manufacturing process.
- Manufacturing process flow chart
- Control of critical steps & intermediates
- Equipment and Premises
- Control of Excipients and Drug Product
- Reference standards,
- Stability data

# Requirements -Phase I CT Applications

molecules- discovered in India



## **SECTION C:**


Non-clinical data along with copy of approval for conducting non-clinical study

## **SECTION D:**

- Covering letter
- Copy of the Protocol
- Form – 44 along with treasury challan for Rs. 50,000/-
- A copy of undertaking and CV of the Investigators along with name and address of the centers where Phase I study will be conducted.
- Case Record Form & Informed Consent
- Investigator Brochure.


# Requirements -Phase I CT applications

**molecules - discovered outside India**



- Data on Phase I CT done in their country or any other countries.
- Approval for conducting Phase I CT from their National Drug Authority.
- Affidavit in support Phase I data
- Details regarding name of the laboratories where analysis will be performed.
- Consent letter form the overseas laboratories for conducting analysis after CT.
- Form -12
- Justification of quantity to be imported for T- license


**First response to New Drug application is 8 to 10 weeks**



# Requirements for Phase II CT

- A copy of the protocol, Informed Consent Form and Case Record Form
- Form - 44 along with treasury challan of Rs. 25000/-
- List of the centres
- Letters of undertaking from the investigators and their CV's
- Name of participating countries and centers (in case of Global CT)
- Preclinical Data
- Clinical data (Results of Phase I)
- Rationale for selecting the proposed dose in the trial
- Regulatory status of the drug in other countries (if applicable)
- Investigator's Brochure
- Regulatory / IRB approvals
- Affidavit in support of Investigator's Brochure
- Affidavit from the sponsor that the study has not been withdrawn from any country ( in case of Global CT)
- Labelling of clinical trial samples.

**First response to Phase II CT application is 6 to 8 weeks**



# Requirements for Phase III CT

- Covering letter
- Form - 44 along with treasury challan of Rs. 25000/-
- Protocol copy
- Undertaking and CV of all the Investigator and details of the Centres
- Investigator Brochure
- Inform consent
- Case Record Form
- Data on Phase II trials
- Stability & dissolution data of the test formulation (not mandatory)
- Labelling of the clinical trial samples
- Regulatory /IRB approvals
- Regulatory status in other countries

**First response to Phase III CT application is 6-8 weeks**



# Pharmacovigilance

## Reporting Serious Adverse Event/ Drug Reaction:


- Death
- Inpatient hospitalization( in case the study was being conducted on out-patients)
- Prolonged hospitalization
- Persistent or significant disability or incapacity
- Congenital anomaly or birth defect
- Life threatening

## Timelines for reporting SAE/SADR

- Report all unexpected SAE/SADR to the Sponsor in 24 hrs
- Report all SAE/SADR to EC within 7 working days
- Report all SAE/SADR to DCGI within 14 calendar days

## PSUR (Periodic Safety Update Reports): To be submitted for all new drugs


- Every 6 months for the first 2 years after approval
- For subsequent years - annually.



# Biotech products

- For biotech product apart from DCGI approval also need approvals from DBT (Department of Biotechnology) & GEAC (Genetic Engineering Approval Committee)
- Parallel Application
- **DBT** is functioning under the Ministry of Science and Technology.
- **GEAC** is functioning under the Ministry of Environment and Forest to examine and issue the clearance from the view point of environmental safety on a case by case basis.

## Application for Biotech Products






# Medical Device

**Definition:** A medical device is defined as an inert diagnostic or therapeutic article that does not achieve any of its principal intended purposes through chemical action, within or on the body unlike the medicated devices which contain pharmacologically active substances which are treated as drugs.

**Following are the medical devices which are considered as drug and are:**


- Cardiac Stents
- Drug Eluting Stents
- Catheters
- Intra Ocular Lenses
- I.V.Cannulae
- Bone Cements
- Heart Valves
- Scalp vein set
- Orthopedic implants
- Internal Prosthetic Replacement



To Summarize---

# Regulatory Approval Process Flowchart for India

## Phase I /BA-BE



Application for Phase I CT / BA-BE Test License /Export of Biological sample will be furnished in single application.

Dossier submission after getting complete documents.

Drugs Controller General of India (DCGI)

**Certificate of Analysis is mandatory while submitting the application for a BA BE study**

Concurrent with main submission of **Phase I CT/ BA-BE application**

2-4 wks (Vaccines)

ICMR particularly For vaccines covering epidemics.

With in 6-10 wks

DCGI

4-6 wks

DCGI approval for **Phase I trial /BA-BE / TL / License for export of biological Samples**

(Total time line will be 12-20 weeks)

2-4 wks (Biologicals)

NIB/Referees

Feedback / NOC with 8-10 wks

DCGI

4-6 wks

DCGI approval for **Phase I CT/BA-BE/TL/License for Export of samples**

(Total time line will be 12-20 weeks)

Genetically modified drugs

DBT/GEAC


with 12-14 wks

NOC from GEAC/Environment


Sent to DCGI 4-6 wks

DCGI approval for **Phase I CT/BA-BE/ TL / License For Export of samples**

(Total time line will be 22-28wks)





# Regulatory Timelines for Study Approval Across Geographic Locations




The comparison of Study review application times of various geographic regions has been compared . The comparison indicates that regulatory approval timelines in India are comparable with that of the EU & USA . The Regulatory timelines for study approval in India are far lesser in comparison with other emerging markets like Brazil & China


# MHRA CTA Assessment Process


## 1st Round





# MHRA CTA Assessment Process 2nd Round






- However, the Indian Regulatory approvals In India takes place as follows (Single round only)



# DCGI -BA BE Assessment Process For All Valid Applications

follows identical pathways to approval as the MHRA




# “Proposals” from DCGI



- Proposal to Create CDA (Central Drugs Authority) of global standards
- To introduce a system of centralized licensing for manufacture of drugs
- Inspection of clinical trial sites will be mandatory.
- To develop knowledge and skill in inspecting CT sites, implementing GCP inspection for which CDSCO has collaborated with US FDA.
- Collaborations with Health Canada, US FDA, Brazil, south Africa to strengthen areas like monitoring drugs for adverse reaction, regulating medical devices, biological drugs.
- Proposal is underway regarding allowing of Phase I molecule for those molecules which are developed outside India

# DCGI Approvals- Yearly Trends- Promising Growth Trends



For the time period Jan-Mar2009, there have been 63 approvals by the DCGI


The same can be projected for the year 2009, the total estimated approvals for the calendar year 2009 could be  $=63*4=252$

## No of DCGI approvals -3 Year Trend

	No of approvals	Time	2006	2007	2008	2009
		No of approvals	161	187	219	252
2006	161					
2007	187					
2008	219					
2009	252					


Projected


### DCGI-Yearly Approval Trends (2009-Projected)




# Case Study

(awarded to Veeda in the past)






# Questions and Answers



THANK YOU

You can write to [info@veedacr.com](mailto:info@veedacr.com) or [call us](#) if you require further information on the subject.



veeda clinical research®



# Unleashing the Power of India

India ■ England ■ Belgium ■ USA ■ Paris